help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lamblin, C.
Right arrow Articles by Tonnel, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lamblin, C.
Right arrow Articles by Tonnel, A. B.

Am. J. Respir. Crit. Care Med., Vol 155, No. 1, Jan 1997, 99-103.

Sequential evaluation of pulmonary function and bronchial hyperresponsiveness in patients with nasal polyposis: a prospective study

C Lamblin, I Tillie-Leblond, J Darras, F Dubrulle, D Chevalier, E Cardot, T Perez, B Wallaert, JJ Piquet and AB Tonnel
Service de Pneumonologie et Immunoallergologie, Hopital A. Calmette and INSERM U416, Institut Pasteur, Lille, France.

Nasal polyposis (NP) is commonly associated with nonspecific bronchial hyperresponsiveness (BHR) and/or asthma. The aim of this prospective study was to investigate the changes of pulmonary function and BHR in patients with nasal polyposis. Forty-four consecutive patients with NP were included in the study and were followed for 12 mo. Nonspecific BHR was assessed by a carbachol challenge test to determine the provocating dose (PD20) necessary to decrease FEV1 by 20% from baseline values; 17 of 22 patients who demonstrated BHR also exhibited asthma. Spirometric measurements and carbachol challenge were performed before initiating any treatment and 12 mo later. All patients were treated first with beclomethasone (600 microg/d). Intranasal ethmoidectomy was performed in 23 patients who did not improve when treated with topical steroids alone (nonresponders); in contrast, 21 patients were successfully treated with beclomethasone alone (responders). PD20 significantly decreased in the group of nonresponders (p = 0.018), whereas it remained unchanged in responders (p = 0.95). FEV1 (% pred) and FEF25-75 (% pred) significantly decreased in nonresponders (p < 0.001), whether BHR existed or not, whereas no significant change was observed in responders. Our results demonstrate that nonresponders who required nasal surgery exhibited an enhancement of BHR and a slight but significant decrease of FEV1 and FEF25-75 values. However, no change in pulmonary symptoms and/or asthma severity occurred. Clinical and functional follow-up of these patients should assess the long-term evolution of these parameters and their clinical relevance.


This article has been cited by other articles:


Home page
 Am. J. Respir. Crit. Care Med.Home page
C. LAMBLIN, F. BOLARD, P. GOSSET, A. TSICOPOULOS, T. PEREZ, J. DARRAS, A. JANIN, A. B. TONNEL, Q. HAMID, and B. WALLAERT
Bronchial Interleukin-5 and Eotaxin Expression in Nasal Polyposis . Relationship with (A)symptomatic Bronchial Hyperresponsiveness
Am. J. Respir. Crit. Care Med., April 1, 2001; 163(5): 1226 - 1232.
[Abstract] [Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. LAMBLIN, A. BRICHET, T. PEREZ, J. DARRAS, A. B. TONNEL, and B. WALLAERT
Long-term Follow-up of Pulmonary Function in Patients with Nasal Polyposis
Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 406 - 413.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1997 American Thoracic Society